Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STOK Stock Forecast 2026-2027
$36.48
Current Price
$2.08B
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STOK Price Targets
+64.5%
To High Target of $60.00
+2.8%
To Median Target of $37.50
-4.1%
To Low Target of $35.00
STOK Price Momentum
+2.8%
1 Week Change
+14.3%
1 Month Change
+349.8%
1 Year Change
+14.9%
Year-to-Date Change
-9.3%
From 52W High of $40.22
+581.9%
From 52W Low of $5.35
📊 TOP ANALYST CALLS
Did STOK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stoke is one of their latest high-conviction picks.
Latest STOK Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, STOK has a bullish consensus with a median price target of $37.50 (ranging from $35.00 to $60.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $36.48, the median forecast implies a 2.8% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Keay Nakae at Chardan Capital, suggesting a 4.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STOK Analyst Ratings
12
Buy
0
Hold
0
Sell
STOK Price Target Range
Low
$35.00
Average
$37.50
High
$60.00
Current: $36.48
Latest STOK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STOK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 24, 2026 | Wolfe Research | Rudy Li | Outperform | Initiates | $40.00 |
| Jan 12, 2026 | Wedbush | Laura Chico | Outperform | Maintains | $36.00 |
| Jan 5, 2026 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $36.00 |
| Jan 5, 2026 | Chardan Capital | Keay Nakae | Buy | Maintains | $35.00 |
| Dec 15, 2025 | HC Wainwright & Co. | Ananda Ghosh | Buy | Maintains | $50.00 |
| Nov 5, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $32.00 |
| Nov 5, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $28.00 |
| Nov 5, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $39.00 |
| Nov 3, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $25.00 |
| Oct 13, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $39.00 |
| Oct 10, 2025 | Needham | Joseph Stringer | Buy | Maintains | $35.00 |
| Aug 13, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $22.00 |
| Aug 13, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Jul 18, 2025 | Jefferies | Andrew Tsai | Buy | Initiates | $30.00 |
| Jul 1, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| May 14, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Apr 9, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $47.00 |
| Mar 19, 2025 | Chardan Capital | Rudy Li | Buy | Maintains | $24.00 |
| Mar 18, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $22.00 |
Stoke Therapeutics Inc. (STOK) Competitors
The following stocks are similar to Stoke based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STOK
Stoke Therapeutics
mkt cap
2.03B
Stoke Therapeutics Inc. (STOK) Financial Data
Stoke Therapeutics Inc. has a market capitalization of $2.08B with a P/E ratio of 53.6x. The company generates $205.63M in trailing twelve-month revenue with a 19.7% profit margin.
Revenue growth is +117.2% quarter-over-quarter, while maintaining an operating margin of -405.3% and return on equity of +15.0%.
Valuation Metrics
Market Cap
$2.08B
Enterprise Value
$1.84B
P/E Ratio
53.6x
PEG Ratio
1.4x
Price/Sales
10.1x
Growth & Margins
Revenue Growth (YoY)
+117.2%
Gross Margin
N/A
Operating Margin
-405.3%
Net Margin
+19.7%
EPS Growth
+117.2%
Financial Health
Cash/Price Ratio
+11.9%
Current Ratio
6.5x
Debt/Equity
1.6x
ROE
+15.0%
ROA
+5.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stoke Therapeutics Inc. (STOK) Business Model
About Stoke Therapeutics Inc.
What They Do
Develops RNA-based treatments for genetic diseases.
Business Model
Stoke Therapeutics operates by leveraging its proprietary TANGO platform to create innovative therapies that specifically target and enhance protein production in tissues affected by genetic disorders. The company focuses on rare diseases, particularly those with significant unmet medical needs, and generates revenue through partnerships, grants, and potential future product sales.
Additional Information
The company's pipeline includes a key program targeting Dravet syndrome, a severe epilepsy condition. Stoke Therapeutics is positioned as a leader in RNA-based therapeutics, addressing genetic diseases that have historically lacked effective treatment options, making it a significant player in the biopharmaceutical market.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
128
CEO
Mr. Ian F. Smith A.C.A., C.P.A.
Country
United States
IPO Year
2019
Website
www.stoketherapeutics.comStoke Therapeutics Inc. (STOK) Latest News & Analysis
Latest News
Quick Summary
Stoke Therapeutics and Biogen announced the publication of zorevunersen study data in NEJM, detailing results from Phase 1/2a trials and ongoing extension studies.
Why It Matters
The publication of zorevunersen data in NEJM could enhance Stoke Therapeutics' credibility and attract investment, while potentially impacting Biogen's stock value based on therapy outcomes.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics (Nasdaq: STOK) announced CEO Ian F. Smith will present at the TD Cowen Health Care Conference on March 3, discussing their investigational drug for Dravet syndrome.
Why It Matters
Stoke Therapeutics' presentation at a major health conference could attract investor interest, signaling potential advancements in its drug development and market opportunities in RNA medicine.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The company focuses on treatments for rare genetic diseases and has a partnership with Biogen.
Why It Matters
Partnerships with established firms like Biogen can enhance credibility, accelerate research, and increase potential market reach for treatments, directly impacting the company's growth prospects and stock value.
Source: Investors Business Daily
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics granted stock options for 22,950 shares of common stock, effective February 17, 2026. The company focuses on RNA medicine for Dravet syndrome treatment.
Why It Matters
Stoke Therapeutics' stock options grant signals confidence in future growth, especially with its innovative treatment for Dravet syndrome, potentially influencing investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics has dosed the first patient in its Phase 1 OSPREY study of STK-002, aimed at treating Autosomal Dominant Optic Atrophy, a rare genetic vision loss disease.
Why It Matters
The dosing of the first patient in the Phase 1 OSPREY study for STK-002 signals progress in Stoke Therapeutics' pipeline, potentially enhancing its market value and investor confidence in innovative therapies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stoke Therapeutics (Nasdaq: STOK) is developing zorevunersen as a potential treatment for Dravet syndrome. CEO Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026.
Why It Matters
Stoke Therapeutics' CEO presentation at a major biotech summit highlights its innovative approach and potential breakthroughs, which could influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About STOK Stock
What is Stoke Therapeutics Inc.'s (STOK) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Stoke Therapeutics Inc. (STOK) has a median price target of $37.50. The highest price target is $60.00 and the lowest is $35.00.
Is STOK stock a good investment in 2026?
According to current analyst ratings, STOK has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $36.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STOK stock?
Wall Street analysts predict STOK stock could reach $37.50 in the next 12 months. This represents a 2.8% increase from the current price of $36.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stoke Therapeutics Inc.'s business model?
Stoke Therapeutics operates by leveraging its proprietary TANGO platform to create innovative therapies that specifically target and enhance protein production in tissues affected by genetic disorders. The company focuses on rare diseases, particularly those with significant unmet medical needs, and generates revenue through partnerships, grants, and potential future product sales.
What is the highest forecasted price for STOK Stoke Therapeutics Inc.?
The highest price target for STOK is $60.00 from at , which represents a 64.5% increase from the current price of $36.48.
What is the lowest forecasted price for STOK Stoke Therapeutics Inc.?
The lowest price target for STOK is $35.00 from Keay Nakae at Chardan Capital, which represents a -4.1% decrease from the current price of $36.48.
What is the overall STOK consensus from analysts for Stoke Therapeutics Inc.?
The overall analyst consensus for STOK is bullish. Out of 17 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $37.50.
How accurate are STOK stock price projections?
Stock price projections, including those for Stoke Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 5:35 PM UTC